News|Videos|November 6, 2023
Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.
Advertisement
Episodes in this series
Advertisement
Related to this article
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
5